Navigation Links
Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
Date:10/12/2007

ANALYST AVAILABLE TO COMMENT ON THE MARKET FORECAST FOR THE DRUG

WALTHAM, Mass., Oct. 12 /PRNewswire/ -- Dr. Sylvia Eash, Ph.D., analyst at Decision Resources, is available to discuss the impact of the Food and Drug Administration's (FDA) possible approval of Merck's Isentress, the first integrase inhibitor drug which blocks the ability of the HIV virus to replicate and infect new cells.

Integrase inhibitors are a novel class of HIV drugs aimed at a previously unexploited viral target. They are a key new class that will expand therapeutic options for HIV patients and stand out as one of the most promising emerging classes in development for HIV. The reported efficacy and safety data from clinical trials of Isentress indicate that the product is highly efficacious, safe, well tolerated in both treatment-naive and treatment-experienced HIV patients. The clinical data on Isentress presented to date suggests that there is significant opportunity for follow-on agents in this new class of HIV drugs.

Isentress is expected to launch during the fourth quarter of 2007, according to Merck.

Dr. Eash can provide:

-- Insight on the class of integrase inhibitors and particularly Isentress

and its potential effect on other drugs in the HIV market.

-- Key factors that will have an impact on Isentress's uptake and use. How

will Isentress be positioned in the lines of HIV treatment?

-- The main drivers and barriers for its use. What is the forecast for

Isentress? Which drugs will be its main competition?

-- Key thought leaders' perceptions about Isentress.

-- Isentress's impact on the HIV market and on the overall HIV therapeutic

approach.

Sylvia Eash, Ph.D., is an analyst with Decision Resources Infectious Disease group, where she evaluates emerging therapies and develops market forecasts. She has a doctoral degree in pathobiology from Brown University. Dr. Eash is the author of several peer-reviewed primary literature and review articles, and she is a member of the American Society for Microbiology and the International Society of Neurovirology.

To talk with Dr. Eash, please contact Erica Ames at 781-296-2583 or eames@dresources.com.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Erica Ames

781-296-2583

eames@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. A Vaccine for the impending pandemic Avian Influenza
2. India warned of Impending AIDS Disaster
3. 3-D Ultrasound Identifies Women at Risk for Impending Preterm Birth
4. Now, Cellphones That Alert Against Impending Lightning Strikes
5. WHO Gives Its Approval For Bird Flu Test Kit
6. Ranbaxy gets US FDA approval for Lisinopril
7. Approval for DNA test to detect cystic fibrosis
8. Aurobindo gets U.S. FDA approval for Cephalexin
9. Cadila gets US FDA approval for Promethazine tablets
10. Vaccine For Cervical Cancer Awaits Approval
11. Anti-obesity drugs for FDA approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... Alexandria, VA (PRWEB) , ... June 23, 2017 ... ... short of what is needed and will ultimately do significant harm to people ... care to everyone. , "While it leaves in place the Affordable Care ...
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, U.S. Senate Republicans ... to repeal and replace the Affordable Care Act (ACA). Like the bill narrowly ... to Medicaid, a public health insurance program for low-income children, pregnant women, parents ...
(Date:6/23/2017)... ... ... The Military Officers Association of America (MOAA) announced its support for the ... Col. Thomas G. Bowman. , Bowman currently serves as the staff director for the ... issues and challenges veterans face with the VA. Following a 30-year career of service ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend and ... to the JFK Virgin Atlantic lounge. , Bensko is no stranger to the ... ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, her ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today announced the ... at 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is ... who owns three other locations in the Topeka and Bonner Springs, Kan. area. ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, ... John Greisch , Hill-Rom,s president and chief executive officer, is ... The live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm ... conclusion of the live event through September 13, 2017. ...
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
Breaking Medicine Technology: